I think the SF drug is more likely to come to market anyways because it is first and foremost an epilepsy drug, and since it is so close to retigabine thats already in the market but without the side effects (I know, its still speculation) theres actually a good chance I would think. Only time will tell if it helps with tinnitus as well though.Now we're going to put all our eggs in the SF00034 basket. Oh, I just can't wait to read in 3-5 years, a similar statement to Autifony's latest release. If targeting specific potassium channels, is the real deal, how and why did AUT00063 fail? Weren't they basically trying to hit the same target?